MARKET

SMMT

SMMT

Summit Therapeutics Inc
NASDAQ
4.540
+0.100
+2.25%
After Hours: 4.490 -0.05 -1.10% 18:06 05/20 EDT
OPEN
4.430
PREV CLOSE
4.440
HIGH
4.570
LOW
4.425
VOLUME
963.03K
TURNOVER
0
52 WEEK HIGH
5.39
52 WEEK LOW
1.300
MARKET CAP
3.19B
P/E (TTM)
-27.4155
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at SMMT last week (0513-0517)?
Weekly Report · 21h ago
SUMMIT THERAPEUTICS - ENTERED INTO DISTRIBUTION AGREEMENT RELATING TO SHARES OF COMMON STOCK OFFERED BY PROSPECTUS SUPPLEMENT
Reuters · 05/13 11:58
SUMMIT THERAPEUTICS INC - MAY OFFER AND SELL SHARES OF COMMON STOCK OF UP TO $90 MLN FROM TIME TO TIME
Reuters · 05/13 11:58
Weekly Report: what happened at SMMT last week (0506-0510)?
Weekly Report · 05/13 09:40
Summit: A Few Catalysts In Q2 Of 2024 To Carry The Tide
Summit Therapeutics Inc. (NASDAQ:SMMT) is gearing up for several catalysts in Q2 of 2024. A decision on whether to approve ivonescimab for the treatment of patients with non-small cell lung cancer is expected in China. The company is also expected to release data from a phase 3 study in the U.S. In 2024. The global non- Small Cell Lung Cancer market is expected to reach $20 billion by 2033.
Seeking Alpha · 05/08 17:30
Summit spikes as Citi launches at Buy on lead asset
Seeking Alpha · 05/07 17:56
Tempur Sealy Posts Upbeat Earnings, Joins FibroGen, Coca-Cola Consolidated, Fabrinet And Other Big Stocks Moving Higher On Tuesday
Shares of Tempur Sealy International, Inc. Rose sharply following upbeat quarterly earnings. The Dow Jones gained over 80 points on Tuesday. Great Lakes Dredge & Dock Corporation shares jumped 31.5% to $9.26. Summit Therapeutics Inc. Shares rose 7% after the company reported better-than-expected quarterly results.
Benzinga · 05/07 14:53
Summit Therapeutics Initiated at Buy by Citigroup
Dow Jones · 05/07 12:27
More
About SMMT
Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician and caregiver medicinal therapies. The Company's development candidate is ivonescimab, a potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. It develops ivonescimab in non-small cell lung cancer (NSCLC), specifically launching Phase III clinical trials in the indications such as ivonescimab combined with chemotherapy in patients with epidermal growth factor receptor (EGFR)-mutated, locally advanced or metastatic non-squamous NSCLC who have progressed after treatment with a third-generation EGFR tyrosine kinase inhibitor (HARMONi), and ivonescimab combined with chemotherapy in first-line metastatic squamous NSCLC patients (HARMONi-3). Its ivonescimab is engineered with Akeso's Tetrabody technology.

Webull offers Summit Therapeutics Inc stock information, including NASDAQ: SMMT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SMMT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SMMT stock methods without spending real money on the virtual paper trading platform.